WallStreetZenWallStreetZen

NASDAQ: KTRA
Kintara Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Should I buy or sell KTRA stock?

Based on 2 analysts offering ratings for Kintara Therapeutics Inc.
Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
2 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their KTRA stock forecasts and price targets.

KTRA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Maxim Group
Bottom 2%
2
HoldDowngradesN/AN/A2022-09-29

1 of 1

Forecast return on equity

Is KTRA forecast to generate an efficient return?
Company
406%
Industry
-0.02%
Market
28.63%
KTRA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is KTRA forecast to generate an efficient return on assets?
Company
270.12%
Industry
0.05%
KTRA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

KTRA earnings per share forecast

What is KTRA's earnings per share in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$0.03
Avg 2 year Forecast
$0.56
Avg 3 year Forecast
$1.48

KTRA revenue forecast

What is KTRA's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$19.6M
Avg 2 year Forecast
$90.9M
Avg 3 year Forecast
$224.0M

KTRA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
KTRA$3.68N/AN/AHold
CMND$2.49N/AN/A
ELOX$2.83$1.00-64.66%Buy
SNPX$0.83$14.00+1,586.75%Strong Buy
XRTX$0.48$17.50+3,545.83%Strong Buy
View Top Biotech Stocks

Kintara Therapeutics Stock Forecast FAQ

Is Kintara Therapeutics Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: KTRA) stock is to Hold KTRA stock.

Out of 2 analysts, 0 (0%) are recommending KTRA as a Strong Buy, 0 (0%) are recommending KTRA as a Buy, 2 (100%) are recommending KTRA as a Hold, 0 (0%) are recommending KTRA as a Sell, and 0 (0%) are recommending KTRA as a Strong Sell.

If you're new to stock investing, here's how to buy Kintara Therapeutics stock.

What is KTRA's Earnings Per Share (EPS) forecast for 2023-2025?

(NASDAQ: KTRA) Kintara Therapeutics's current Earnings Per Share (EPS) is -$14.60. On average, analysts forecast that KTRA's EPS will be $0.03 for 2023, with the lowest EPS forecast at $0.03, and the highest EPS forecast at $0.03. On average, analysts forecast that KTRA's EPS will be $0.56 for 2024, with the lowest EPS forecast at $0.56, and the highest EPS forecast at $0.56. In 2025, KTRA's EPS is forecast to hit $1.48 (min: $1.48, max: $1.48).

What is KTRA's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: KTRA) forecast ROE is 406%, which is considered strong.

What is KTRA's earnings growth forecast for 2023-2025?

(NASDAQ: KTRA) Kintara Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.41%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.51%.

Kintara Therapeutics's earnings in 2023 is -$19,222,000.On average, 1 Wall Street analyst forecast KTRA's earnings for 2023 to be $50,259, with the lowest KTRA earnings forecast at $50,259, and the highest KTRA earnings forecast at $50,259. On average, 1 Wall Street analyst forecast KTRA's earnings for 2024 to be $938,171, with the lowest KTRA earnings forecast at $938,171, and the highest KTRA earnings forecast at $938,171.

In 2025, KTRA is forecast to generate $2,479,451 in earnings, with the lowest earnings forecast at $2,479,451 and the highest earnings forecast at $2,479,451.

What is KTRA's revenue growth forecast for 2023-2025?

(NASDAQ: KTRA) Kintara Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 40.15%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.77%.

Kintara Therapeutics's revenue in 2023 is $0.On average, 1 Wall Street analysts forecast KTRA's revenue for 2023 to be $32,902,990, with the lowest KTRA revenue forecast at $32,902,990, and the highest KTRA revenue forecast at $32,902,990. On average, 1 Wall Street analysts forecast KTRA's revenue for 2024 to be $152,335,484, with the lowest KTRA revenue forecast at $152,335,484, and the highest KTRA revenue forecast at $152,335,484.

In 2025, KTRA is forecast to generate $375,268,320 in revenue, with the lowest revenue forecast at $375,268,320 and the highest revenue forecast at $375,268,320.

What is KTRA's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: KTRA) forecast ROA is 270.12%, which is higher than the forecast US Biotechnology industry average of 0.05%.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.